Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $200
Express News | Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $200
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $180
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
Why Is BioMarin Stock Trading Higher On Thursday?
Express News | Form 144 | Ascendis Pharma A/S(ASND.US) Officer Proposes to Sell 6.01 Million in Common Stocks
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $180 to $289
Express News | Ascendis Pharma Shares Are Trading Higher After Evercore ISI Raised Its Price Target on the Stock From $220 to $260
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading
Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group
The 19% Return This Week Takes Ascendis Pharma's (NASDAQ:ASND) Shareholders Three-year Gains to 29%
The Ascendis Pharma A/S (NASDAQ:ASND) Yearly Results Are Out And Analysts Have Published New Forecasts
Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $220
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $168 to $225
Ascendis Pharma AS (ASND) Q4 2024 Earnings Call Highlights: Strategic Growth and Market ...
Top Gap Ups and Downs on Thursday: APP, SONY, TTD and More
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading